BioCardia, Inc. (BCDA)
Last updated: 2026-10-24 15:04:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
BioCardia, Inc. (BCDA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.93, with a market capitalization of $14.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.75 to $1.80. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$14.06M | |
$0.95 | |
$129.00 | |
$0.75 | |
$0.93 | |
39.06K | |
251.16K | |
-- | |
$1.80 | |
$0.75 | |
-- | |
-- |
BioCardia, Inc. (BCDA) Latest Closing Stock Price
BioCardia, Inc. (BCDA) last closed at $0.93 as of 2026-10-23 23:56:00, unchanged from the previous close of $0.93.
During the latest regular trading session, BCDA traded between $0.75 and $129.00, with a volume of 39.06K shares. The closing price was near the lower end and near the lower end of its 52-week range.
BioCardia, Inc. (BCDA) 7-Day Stock Price Change
Over the past seven days, BioCardia, Inc. (BCDA) moved from $0.94 to $0.93, representing a decline of 1.33% ($0.01).
The stock traded between $0.87 and $1.07 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 174.68 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
BCDA 52-Week Price Position
Position in Range: 16.8%
BCDA is currently trading at $0.93, placing it 16.8% of the way from its 52-week low of $0.75 to its 52-week high of $1.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is BioCardia, Inc. (BCDA)?
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
BioCardia, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
How to Buy BioCardia, Inc. (BCDA) Stock on MEXC
Eligible investors can buy real shares of BioCardia, Inc. (BCDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is BioCardia, Inc. (BCDA) stock price today?
2.Is BCDA stock going up or down today?
3.What is BCDA pre-market price?
4.What is BCDA after-hours price?
5.Is BCDA stock trading now?
6.Where does BCDA sit relative to its 52-week high and low?
7.What sector is BioCardia, Inc. in?
8.What is BioCardia, Inc.'s market capitalization and where is it listed?
9.How is BCDA valued in terms of P/E ratio and EPS?
10.Does BioCardia, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BCDA Stock Calculator
Estimate the value between BCDA shares and USD.
BCDA Shares to USD
1.00 BCDA shares = 0.926 USD
Calculations are estimates based on the latest available price and are for reference only.


